Preprint
Inhalation: A means to explore and optimize nintedanib’s pharmacokinetic/pharmacodynamic relationship
Abstract
ABSTRACT Oral nintedanib is marketed for the treatment of idiopathic pulmonary fibrosis (IPF). While effective slowing fibrosis progression, as an oral medicine nintedanib is limited. To reduce side effects and maximize efficacy, nintedanib was reformulated as a solution for nebulization and inhaled administration. To predict effectiveness treating IPF, the nintedanib pharmacokinetic/pharmacodynamic relationship was dissected. Pharmacokinetic …
Authors
Epstein-Shochet G; Pham S; Beck S; Naiel S; Mekhael O; Revill S; Hayat A; Vierhout M; Bardestein-Wald B; Shitrit D
DOI
10.1101/2020.03.27.012401
Preprint server
bioRxiv